Stock Track | PROCEPT BioRobotics Plunges 21.73% in Post-Market on Q4 Earnings Miss

Stock Track

Feb 26

PROCEPT BioRobotics (PRCT) experienced a significant post-market plunge of 21.73% on Wednesday.

The sharp decline followed the company's release of its fourth-quarter 2025 financial results, which fell short of analyst expectations. PROCEPT reported a quarterly loss per share of $(0.53), missing the consensus estimate of $(0.32) by a wide margin. Revenue for the quarter was $76.383 million, also below the estimated $94.137 million. Furthermore, the company's adjusted EBITDA loss of $19.013 million was significantly worse than the anticipated loss of $2.8 million.

CEO Larry Wood stated that the revenue shortfall was due to strategic actions including a commercial organization realignment, the elimination of end-of-quarter purchasing incentives, and a more disciplined handpiece pricing strategy. While the company reported its highest procedure volume to date and provided a revenue growth outlook of 27-33% for 2026, the substantial misses on key quarterly metrics drove the negative investor reaction.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1141413655"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1141413655\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1141413655?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 09:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141413655","market":"nz","top_or_hot":-1,"title":"Stock Track | PROCEPT BioRobotics Plunges 21.73% in Post-Market on Q4 Earnings Miss","media":"Stock Track","content":"<p>PROCEPT BioRobotics (PRCT) experienced a significant post-market plunge of 21.73% on Wednesday.</p><p>The sharp decline followed the company's release of its fourth-quarter 2025 financial results, which fell short of analyst expectations. PROCEPT reported a quarterly loss per share of $(0.53), missing the consensus estimate of $(0.32) by a wide margin. Revenue for the quarter was $76.383 million, also below the estimated $94.137 million. Furthermore, the company's adjusted EBITDA loss of $19.013 million was significantly worse than the anticipated loss of $2.8 million.</p><p>CEO Larry Wood stated that the revenue shortfall was due to strategic actions including a commercial organization realignment, the elimination of end-of-quarter purchasing incentives, and a more disciplined handpiece pricing strategy. While the company reported its highest procedure volume to date and provided a revenue growth outlook of 27-33% for 2026, the substantial misses on key quarterly metrics drove the negative investor reaction.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | PROCEPT BioRobotics Plunges 21.73% in Post-Market on Q4 Earnings Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | PROCEPT BioRobotics Plunges 21.73% in Post-Market on Q4 Earnings Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-26 09:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PROCEPT BioRobotics (PRCT) experienced a significant post-market plunge of 21.73% on Wednesday.</p><p>The sharp decline followed the company's release of its fourth-quarter 2025 financial results, which fell short of analyst expectations. PROCEPT reported a quarterly loss per share of $(0.53), missing the consensus estimate of $(0.32) by a wide margin. Revenue for the quarter was $76.383 million, also below the estimated $94.137 million. Furthermore, the company's adjusted EBITDA loss of $19.013 million was significantly worse than the anticipated loss of $2.8 million.</p><p>CEO Larry Wood stated that the revenue shortfall was due to strategic actions including a commercial organization realignment, the elimination of end-of-quarter purchasing incentives, and a more disciplined handpiece pricing strategy. While the company reported its highest procedure volume to date and provided a revenue growth outlook of 27-33% for 2026, the substantial misses on key quarterly metrics drove the negative investor reaction.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRCT","symbol_name":"PROCEPT BioRobotics","start_time":0,"source_url":"","article_id":"1141413655","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141413655","pubTimestamp":1772067835,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"PROCEPT BioRobotics (PRCT) experienced a significant post-market plunge of 21.73% on Wednesday.The sharp decline followed the company's release of its fourth-quarter 2025 financial results, which...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRCT":"PROCEPT BioRobotics"},"translate_title":"个股追踪|PROCEPT BioRobotics盘后暴跌21.73%财报未达预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRCT":1},"content_text":"PROCEPT BioRobotics (PRCT) experienced a significant post-market plunge of 21.73% on Wednesday.The sharp decline followed the company's release of its fourth-quarter 2025 financial results, which fell short of analyst expectations. PROCEPT reported a quarterly loss per share of $(0.53), missing the consensus estimate of $(0.32) by a wide margin. Revenue for the quarter was $76.383 million, also below the estimated $94.137 million. Furthermore, the company's adjusted EBITDA loss of $19.013 million was significantly worse than the anticipated loss of $2.8 million.CEO Larry Wood stated that the revenue shortfall was due to strategic actions including a commercial organization realignment, the elimination of end-of-quarter purchasing incentives, and a more disciplined handpiece pricing strategy. While the company reported its highest procedure volume to date and provided a revenue growth outlook of 27-33% for 2026, the substantial misses on key quarterly metrics drove the negative investor reaction.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}